FOCUS on Drug Approvals. On December 17th the FDA granted regular approval to PARP inhibitor drug Rubraca (Rucaparib, pharmaand GmbH), for treatment of adults with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer. This converts the FDA’s accelerated approval (May, 2020) to a full approval.
Focus Biomolecules offers Rucaparib for research applications.
